Risks
4 risks
Risk Intelligence
FDA inspection delays for key biosimilars
View Risks →Biocon Limited — Q3 FY24
Biocon's Q3 FY24 consolidated revenue from operations grew 34% YoY to INR 3,954 crore, driven by a 65% surge in biosimilars revenue, partially offset by a 7% decline in generics.
neutral
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Biocon's Q3 FY24 consolidated revenue from operations grew 34% YoY to INR 3,954 crore, driven by a 65% surge in biosimilars revenue, partially offset by a 7% decline in generics. Core EBITDA margin stood at 27%, impacted by integration-related one-offs in Biocon Biologics (BBL). Reported PAT was INR 660 crore, boosted by non-recurring gains from divestitures and Bicara stake dilution. BBL completed the Viatris integration 12 months ahead of schedule, but FDA inspection delays for key biosimilars (Aspart, Bevacizumab) and pricing pressure in generics API remain headwinds. Management guided for margin improvement as one-off costs subside and new product approvals materialize, though timelines remain uncertain. Key risk: further delays in FDA inspections could prolong margin pressure and delay debt reduction.
बायोकॉन की तीसरी तिमाही में कमाई पिछले साल से 34% बढ़कर 3,954 करोड़ रुपये हो गई। इसकी मुख्य वजह बायोसिमिलर (महंगी दवाओं के सस्ते विकल्प) की बिक्री में 65% का उछाल है, जबकि जेनेरिक दवाओं की बिक्री 7% गिरी। कंपनी का मुनाफा 660 करोड़ रुपये रहा, जो कुछ संपत्ति बेचने और निवेश से हुए एकमुश्त फायदे से बढ़ा। हालांकि, कुछ खास दवाओं के लिए एफडीए (अमेरिकी दवा नियामक) की मंजूरी में देरी और जेनेरिक दवाओं पर कीमत का दबाव चिंता का विषय है। कंपनी का कहना है कि एक बार के खर्च कम होने और नई दवाओं की मंजूरी मिलने पर मुनाफा बढ़ेगा, लेकिन समय सीमा अनिश्चित है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Fulphila U.S. market share
19%
+12pp vs prior month
Fulphila market share increased to 19% in November, up from 7% in the prior month, driven by new contract wins.
Ogivri U.S. market share
12%
stable
Ogivri maintained a 12% market share, with new GPO contracts secured during the quarter.
Insulin Glargine total U.S. market share
16-17%
+4-5pp vs reported 12%
Including unbranded Glargine through closed-door pharmacy, total insulin glargine share is estimated at 16-17%.
Fulphila Europe market share
8%
+3pp YoY
Fulphila's quarterly market share in Europe grew to 8% from 5% a year ago, reflecting steady gains.
What Changed vs Last Quarter
NEW
BBL core EBITDA margin target of mid-30s
Management reiterated a mid-30s core EBITDA margin target for Biocon Biologics, with current margins depressed by ~5% due to integration-related one-off costs expected to normalize.
NEW
Generics business targeting mid-teens growth next fiscal
Generics business aims to return to mid-teens growth in FY25, driven by formulations momentum and new peptide revenues, despite current API pricing pressure.
NEW
Debt reduction focus with $200M repaid in Q3
Management emphasized continued debt reduction, having repaid $200M of acquisition debt in Q3, with further deleveraging expected from cash flows and other options.
NEW
Syngene facility operational in H2 FY25
The acquired Stelis biologics facility is expected to be operational in the second half of FY25, subject to regulatory approvals, adding 20,000L capacity.
DROPPED
Biocon Biologics to deliver $1 billion revenue in FY24
Management reaffirmed full-year revenue guidance of $1 billion for Biocon Biologics, driven by market share gains and new product launches.
DROPPED
Syngene mid-teen constant currency growth for FY24
Syngene is expected to deliver mid-teen constant currency growth for the full year, supported by strong performance in development and manufacturing services.
DROPPED
Generics H2 performance to improve over H1
Generics business expects improved second half performance, with formulations steady at ~INR 400 crore per half and API recovery, but full-year growth revised to low teens/high single digit.
DROPPED
Ustekinumab filing on track by end of 2023
Biocon Biologics remains on track to file ustekinumab (Stelara biosimilar) before the end of 2023, with denosumab filing expected by end of next year.
NEW RISK
FDA inspection delays for key biosimilars
Approvals for Aspart and Bevacizumab are delayed due to FDA's inability to inspect sites, with no clear timeline for resolution, potentially impacting revenue growth and margin expansion.
NEW RISK
Adalimumab market opening slower than expected
The U.S. Adalimumab biosimilar market is expected to open meaningfully only in CY2025, delaying potential revenue contribution from this large opportunity.
RISK GONE
Regulatory delays at Malaysia facility
FDA issued a CRL for insulin aspart due to pre-approval inspection deficiencies at the Malaysia facility; resolution timeline uncertain.
RISK GONE
Slower adalimumab (Hulio) uptake in US
Market adoption of adalimumab biosimilars has been slower than anticipated, impacting Hulio's revenue contribution; management expects improvement only in 2024-25.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Net debt to EBITDA elevated; interest costs rising due to high rate environment; deferred payments in FY25 may require additional funding.
Mentioned in Q1 FY24, Q2 FY24
Syngene is expected to deliver mid-teen constant currency growth for the full year, supported by strong performance in development and manufacturing services.
Fast read
Guidance and risk preview
Management reiterated a mid-30s core EBITDA margin target for Biocon Biologics, with current margins depressed by ~5% due to integration-related on...
Approvals for Aspart and Bevacizumab are delayed due to FDA's inability to inspect sites, with no clear timeline for resolution, potentially impact...
View Risks →